Madrigal 10-Q Details First Profitable Quarter, $961.8M Cash, EPS Restatement and New SOX Suit
MDGL is trading near its 52-week low of $399 (7.3% above the low) on elevated volume (1.8× avg).
Summary
Madrigal's 10-Q confirms the first profitable quarter ($55.4 million net income on $431.3 million of Rezdiffra sales) already reported this morning, and adds $961.8 million of cash, a restated EPS presentation, and disclosure of a new SOX whistleblower lawsuit filed October 9, 2026.
Key Events · Earnings and Guidance · MDGL
-
First Profitable Quarter Confirmed
Q3 2026 product revenue of $431.3 million versus $287.3 million a year earlier (+50%), producing $55.4 million of net income and $1.83 diluted EPS — the company's first profitable quarter.
-
Cash Position and Debt Terms
Cash, cash equivalents, restricted cash and marketable securities totaled $961.8 million at September 30, 2026, against $350.0 million outstanding on the Blue Owl term loan at an 8.48% rate and a $100.0 million minimum unrestricted cash covenant; the company says liquidity funds operations past one year.
-
EPS Presentation Restated
Pre-Funded Warrants and Series A/B Preferred are now included in basic and diluted share counts, revising FY2025 net loss per share to $(10.15) from $(12.85) and the nine months ended 9/30/25 to $(8.12) from $(10.32); management deemed the change immaterial.
-
New Whistleblower Lawsuit Disclosed
A former employee filed Charlton v. Madrigal Pharmaceuticals, Inc. on October 9, 2026 in the Northern District of Illinois, alleging SOX retaliation over internal concerns about data and reporting practices; the company disputes the claims and plans to defend.
Analysis · MDGL · Life Sciences
The headline numbers — $431.3 million of Q3 Rezdiffra sales and $55.4 million of net income, or $1.83 diluted EPS — were already out via this morning's 8-K, so the print itself is not new. What the 10-Q adds is the balance sheet behind it: $961.8 million of cash, equivalents and marketable securities at September 30, 2026, against a $350.0 million term loan at 8.48% and a $100.0 million minimum-cash covenant, which puts the company well past the financing risk that dominated its loss-making years. Two items deserve attention. First, the company revised its earnings-per-share presentation to fold the Pre-Funded Warrants and Series A/B Preferred into basic and diluted share counts, cutting previously reported per-share losses (FY2025 goes from $(12.85) to $(10.15)); management judged the change immaterial, but it changes the share base investors should use. Second, a former employee sued on October 9, 2026 under the Sarbanes-Oxley whistleblower provisions, alleging retaliation after raising internal concerns about data and reporting practices — the company disputes it and no reserve is recorded. The nine-month picture is still a $96.9 million net loss on a $2,187.4 million accumulated deficit, so one profitable quarter does not yet make a trend.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDGL was trading at $428.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $399.00 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.